My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 1306

    1.

    Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.

    Eddy DM, Schlessinger L, Kahn R.

    Ann Intern Med. 2005 Aug 16;143(4):251-64.PMID: 16103469 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance.

    Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, Hamman RF, Ackermann RT, Engelgau MM, Ratner RE; Diabetes Prevention Program Research Group.

    Ann Intern Med. 2005 Mar 1;142(5):323-32.PMID: 15738451 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.

    Diabetes Prevention Program Research Group.

    Diabetes Care. 2003 Sep;26(9):2518-23.PMID: 12941712 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Summaries for patients. The outcomes and costs of diabetes prevention with a diet and exercise program or metformin: a computer model.

    [No authors listed]

    Ann Intern Med. 2005 Aug 16;143(4):I22. No abstract available. PMID: 16103465 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.

    Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC, Smith WC, Jung RT, Campbell MK, Grant AM.

    Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. Review.PMID: 15147610 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: modeling the long-term health economic implications of the diabetes prevention program in Australia, France, Germany, Switzerland, and the United Kingdom.

    Palmer AJ, Roze S, Valentine WJ, Spinas GA, Shaw JE, Zimmet PZ.

    Clin Ther. 2004 Feb;26(2):304-21.PMID: 15038953 [PubMed - indexed for MEDLINE]Related articles

    7.

    Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000.

    Icks A, Rathmann W, Haastert B, Gandjour A, Holle R, John J, Giani G; KORA Study Group.

    Diabet Med. 2007 May;24(5):473-80. Epub 2007 Mar 22.PMID: 17381502 [PubMed - indexed for MEDLINE]Related articles

    8.

    [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations]

    Flórez H.

    Invest Clin. 1997 Mar;38(1):39-52. Review. Spanish. PMID: 9235072 [PubMed - indexed for MEDLINE]Related articles

    9.

    Screening for type 2 diabetes: literature review and economic modelling.

    Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, Williams R, John A.

    Health Technol Assess. 2007 May;11(17):iii-iv, ix-xi, 1-125. Review.PMID: 17462167 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.

    Palmer AJ, Roze S, Lammert M, Valentine WJ, Minshall ME, Nicklasson L, Gall MA, Spinas GA.

    Curr Med Res Opin. 2004 Aug;20 Suppl 1:S41-51.PMID: 15324515 [PubMed - indexed for MEDLINE]Related articles

    11.

    The cost-effectiveness of screening for type 2 diabetes. CDC Diabetes Cost-Effectiveness Study Group, Centers for Disease Control and Prevention.

    [No authors listed]

    JAMA. 1998 Nov 25;280(20):1757-63. Erratum in: JAMA 1999 Jan 27;281(4):325. PMID: 9842951 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program.

    Hernan WH, Brandle M, Zhang P, Williamson DF, Matulik MJ, Ratner RE, Lachin JM, Engelgau MM; Diabetes Prevention Program Research Group.

    Diabetes Care. 2003 Jan;26(1):36-47.PMID: 12502656 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Economic evaluation of therapeutic interventions to prevent Type 2 diabetes in Canada.

    Caro JJ, Getsios D, Caro I, Klittich WS, O'Brien JA.

    Diabet Med. 2004 Nov;21(11):1229-36.PMID: 15498090 [PubMed - indexed for MEDLINE]Related articles

    14.

    Cost-effectiveness of vaccination against invasive pneumococcal disease among people 50 through 64 years of age: role of comorbid conditions and race.

    Sisk JE, Whang W, Butler JC, Sneller VP, Whitney CG.

    Ann Intern Med. 2003 Jun 17;138(12):960-8.PMID: 12809452 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis.

    Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, Davies MJ, Khunti K.

    BMJ. 2008 May 24;336(7654):1180-5. Epub 2008 Apr 21.PMID: 18426840 [PubMed - indexed for MEDLINE]Related articlesFree article

    16.

    Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes.

    Ray JA, Boye KS, Yurgin N, Valentine WJ, Roze S, McKendrick J, Tucker DM, Foos V, Palmer AJ.

    Curr Med Res Opin. 2007 Mar;23(3):609-22.PMID: 17355742 [PubMed - indexed for MEDLINE]Related articles

    17.

    The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial.

    Orchard TJ, Temprosa M, Goldberg R, Haffner S, Ratner R, Marcovina S, Fowler S; Diabetes Prevention Program Research Group.

    Ann Intern Med. 2005 Apr 19;142(8):611-9.PMID: 15838067 [PubMed - indexed for MEDLINE]Related articlesFree article

    18.

    Screening for type 2 diabetes mellitus: a cost-effectiveness analysis.

    Hoerger TJ, Harris R, Hicks KA, Donahue K, Sorensen S, Engelgau M.

    Ann Intern Med. 2004 May 4;140(9):689-99.PMID: 15126252 [PubMed - indexed for MEDLINE]Related articlesFree article

    19.

    Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

    Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group.

    N Engl J Med. 2002 Feb 7;346(6):393-403.PMID: 11832527 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.

    Shearer AT, Bagust A, Ampudia-Blasco FJ, Martínez-Lage Alvarez B, Pérez Escolano I, París G.

    Pharmacoeconomics. 2006;24 Suppl 1:49-59. Review.PMID: 16800162 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity